Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products for patients in Greater China and other parts of Asia today announced that Spero Therapeutics, Inc. (Nasdaq: SPRO), a licensing partner of Everest Medicines, entered into a regional licensing agreement with Pfizer Inc. (NYSE: PFE) for SPR206, Spero's intravenously (IV)-administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting.

Under the terms of the licensing agreement, Spero has granted Pfizer the rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex- Asia territories. In exchange for these rights, Spero is eligible to receive up to $80 million in development and sales milestones, and high single digit to low double-digit royalties on net sales of SPR206 in these territories. Pfizer has also made a $40 million equity investment in Spero as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs.

Under a licensing agreement with Spero that was announced in January of 2019, Everest Medicines has exclusive rights to develop, manufacture and commercialize SPR206 in Greater China , South Korea and certain Southeast Asian countries (the "Territory") for the treatment of multi-drug resistant (MDR) Gram-negative bacterial infections. The licensing agreement was amended in January 2021 for the assignment of relevant patents for SPR206 in the Territory to Everest. This license agreement between Spero and Pfizer will have no impact on Everest's rights for SPR206.

"This deal reinforces the potential for SPR206 to serve as an innovative treatment option for MDR Gram-negative bacterial infections, which is a critical ongoing global public health issue," said Kerry Blanchard , MD, PhD, CEO of Everest Medicines. "Pfizer is a leader in the anti-infective therapeutic space, and Pfizer's decision to partner with Spero on this important asset is a testament to Everest's strategic approach to choosing promising and valuable development-stage global assets. We look forward to contributing to the broad and rapid clinical development of SPR206 as we work to address the challenges of MDR Gram-negative bacterial infections."

About SPR206

SPR206 is a potentially best-in-class, novel polymyxin derivative that was designed to reduce the kidney toxicity that is seen clinically with polymyxin B and colistin. Polymyxins are antibiotics frequently used as a last resort for challenging MDR gram-negative infections, but they are associated with significant neurotoxicity and nephrotoxicity. In a double-blind, placebo-controlled Phase 1 clinical trial in healthy volunteers conducted by our partner Spero Therapeutics, SPR206 appeared well tolerated at doses likely to be within a therapeutic range for MDR Gram-negative bacterial infections. Importantly, it also showed no evidence of nephrotoxicity at the doses tested.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development. The Company's therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit its website at www.everestmedicines.com .

Cision View original content: https://www.prnewswire.com/news-releases/everest-medicines-announces-that-spero-therapeutics-entered-into-licensing-agreement-with-pfizer-inc-for-spr206-in-ex-us-and-ex-asia-territories-301325440.html

SOURCE Everest Medicines

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Jamieson Wellness Inc. Reports Strong Fourth Quarter and Full Year 2023 Results

Profitable revenue growth of 23.5% in 2023 demonstrates successful execution of global strategy;
Canadian consumer consumption reaches record levels in Q4

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported financial results for its fourth quarter and full year results for the period ended December 31, 2023. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See "Non-IFRS and Other Financial Measures" below.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Announces Date of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company will release its fourth quarter and full year 2023 financial results after the market close on Wednesday, March 13, 2024. The Company will host a conference call for investors at 5:00 p.m. Eastern Time to discuss the fourth quarter and full year 2023 results.

The call can be accessed live over the telephone by dialing 1-888-886-7786 from Canada and the U.S. or 1-416-764-8658 from international locations. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 82012546 and it will be available until Thursday, March 27, 2024.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Declares Fourth Quarter 2023 Dividend

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the board of directors of the Company has declared a cash dividend for the fourth quarter of 2023 of $0.19 per common share, or approximately $8.0 million in the aggregate. The dividend will be paid on March 15, 2024 to all common shareholders of record at the close of business on March 1, 2024. The Company has designated this dividend as an "eligible dividend" for the purposes of the Income Tax Act (Canada).

About Jamieson Wellness Inc.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx for Recurrent Pericarditis

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx for Recurrent Pericarditis

Topline Results Expected in Q2 2024

This is a Designated News Release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Principal Technologies (TSXV:PTEC)

Principal Technologies


Keep reading...Show less
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study

This is a Designated News Release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×